ArticleCureus2024
An Investigation Into Carbapenem Resistance in Enterobacteriaceae Among Outpatients With Urinary Tract Infection in Southwestern Uganda.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multiplex PCR-Based Detection of Eight Carbapenemase Genes and Their Clinical Characteristics in Urinary Tract Infections.Antibiotics (Basel, Switzerland) · 2026Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim Urinary tract infections (UTIs) are among the most common bacterial infections worldwide, primarily caused by Enterobacteriaceae. The rise of carbapenem-resistant Enterobacteriaceae (CRE), complicates treatment of UTIs, yet the distribution of CRE and carbapenemase genes in Uganda's hospitals is not sufficiently explored. This study aimed to examine the distribution of carbapenemase genes in Enterobacteriaceae isolated from urinary tract infections in outpatients in southwestern Uganda. Methods A cross-sectional hospital-based study was conducted in southwestern Uganda. The study involved 111 participants who tested positive for carbapenemase genes. These participants were selected from a total of 2,371 patients presenting with urinary tract infections (UTIs) at Bwizibwera Health Center IV and Rubaya Health Center III. Enterobacteriaceaewere identified using a series of biochemical tests, and the presence of carbapenemase resistance genes (blaVIM, blaOXA-48, blaNDM, blaKPC, and blaIMP) was confirmed through polymerase chain reaction (PCR) genotyping. Data were analyzed and presented as frequencies and proportions, displayed in tables and charts. Results We screened a total of 2,371 participants with symptoms of urinary tract infections (UTI) for Enterobacteriaceae, 455 (19.2%) tested positive for at least one of the Enterobacteriaceae species. Disk susceptibility testing (DST) for carbapenems (meropenem and ertapenem) revealed a phenotypic carbapenem resistance prevalence of 5.7% (26/455), while polymerase chain reaction (PCR) identified a genotypic prevalence of 24.4% (111/455).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.